Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A human
monoclonal antibody which is being studied in the treatment ofbone disorders such asosteoporosis .
Etymologies
from Wiktionary, Creative Commons Attribution/Share-Alike License
Support
Help support Wordnik (and make this page ad-free) by adopting the word denosumab.
Examples
-
The study compared Prolia, also known by its generic name denosumab, with Zometa, a
-
The disappointing revenue numbers for the Thousand Oaks, Calif., company -- highlighted by a 20% decline in sales of arthritis drug Enbrel -- increases the stakes for the success of Amgen's experimental bone drug denosumab, which is expected to get an approval decision from the Food and Drug Administration in October.
-
The news comes on the back of the success of a study of its lead drug candidate, bone-loss drug denosumab, which is hoped to reinvigorate growth at the company, overcoming the stagnant growth of its EPO anemia drugs -- Aranesp and Epogen.
-
Critical to Amgen's plans is gaining regulatory approval for its experimental bone-strengthening drug, called denosumab, and launching it successfully in an already crowded $7 billion global market for osteoporosis treatments.
-
The new drug, called denosumab, or D-mab, was previously shown to increase bone mass in people at risk for the brittle-bone disease osteoporosis.
-
WEDNESDAY, Feb. 23 (HealthDay News) -- A new drug called denosumab (Xgeva) performed somewhat better than the current standard treatment of zoledronic acid (Zometa) for preventing fractures and other bone problems in men with hormone-resistant prostate cancer, a new study suggests.
-
Food and Drug Administration cleared the drug, also known as denosumab, to reduce fracture risks in breast cancer patients taking drugs that halt estrogen production and prostate cancer patients treated with androgen-deprivation therapies, Thousand Oaks, California-based Amgen said today in a statement.
unknown title 2011
-
WEDNESDAY, Feb. 23 (HealthDay News) -- A new drug called denosumab (Xgeva) performed somewhat better than the current standard treatment of zoledronic acid (Zometa) for preventing fractures and other bone problems in men with hormone-resistant prostate cancer, a new study suggests.
-
Yesterday Amgen released positive results from its third phase 3 trial pitting Prolia (aka denosumab) against Novartis '(NYSE: NVS) Zometa in prostate cancer patients whose tumors had spread to the bone.
-
The biotechnology firm announced that a much-awaited study of its bone drug Xgeva also known as denosumab, and sold for osteoporosis as Prolia prevented prostate cancer from spreading to the bone in patient whose levels of prostate-specific antigen are rising.
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.